Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 MmTUR4VtdCCYaXHibYxqfHliQYPzZZk> MVWwMVAvPSEQvF2= MUGyOEBp NVfzW4p[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= MUGyOVY3Ozd4OR?=
HepG2-HBV1.1 MnLIRZBweHSxc3nzJGF{e2G7 MoHmNE0xNjVizszN NXvibJptOjRiaB?= M{juWolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M3XjVVI2PjZ|N{[5
HepG2.2.15 Mm[4SpVv[3Srb36gRZN{[Xl? M2XRNFAvOSEQvF2= M1rTZVI1KGh? MmHXdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NEXpSGgzPTZ4M{e2PS=>
HepG2-HBV1.1 NF7JVWdHfW6ldHnvckBCe3OjeR?= NV2zXlhDOC5zIN88US=> Mmf4NlQhcA>? M2PEW5Bzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NHjwOHkzPTZ4M{e2PS=>
HepG2-HBV1.1 MUHGeY5kfGmxbjDBd5NigQ>? MVWwMlEh|ryP MoHHOFghcA>? MkXNdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ M2SzSlI2PjZ|N{[5
HepG2-HBV1.1 NXWzfFdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLWNE4yKM7:TR?= MonpNU02KGR? NEjueWtqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NWPYVpF[OjV4NkO3Olk>
HepG2-HBV1.1 M{nxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMlEh|ryP MmnzNU02KGR? NEfu[FFqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 M1rpS|I2PjZ|N{[5
HepG2-HBV1.1 M33Tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMlEh|ryP MmPZNVIuPzJiaB?= NXrrcllIcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm M2iyR|I2PjZ|N{[5
HepG2-HBV1.1 M3XXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSwMlEh|ryP M3nqUVEzNTd{IHi= MkewbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl MWiyOVY3Ozd4OR?=
Raji NI\ZNo5HfW6ldHnvckBCe3OjeR?= MXWwMlXDqM7:TR?= MlLhO|IhcA>? M4G2VIFjd2yrc3jld{BifXSxcHjh[5nDqA>? MYWyOVQ1PjN5Nx?=
SK-MEL-28  MWrGeY5kfGmxbjDBd5NigQ>? Mo\yN|Ahdk1? MWi2JIg> MWPpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? MnTCNlU{OTNyMUC=
H157 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX5b4xKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= NVrXZlg1OjV{NUe5NVE>
Jurkat M2GzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLYNU0{KG6P MV[0POKhcA>? NFrI[I9FVVOR MW\k[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NYq3c2ZbOjVzNU[xOFY>
CEM MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TIV|EuOyCwTR?= M2jlfFQ5yqCq NF;HdJZFVVOR Mljj[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> MVmyOVE2PjF2Nh?=
P12 M2\tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTJNU0{KG6P NF7Qemc1QMLiaB?= NYKwb5hoTE2VTx?= M4HzWIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MVOyOVE2PjF2Nh?=
KB NGjPenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP MXiyOVA2QDV{Nh?=
KBv200 (ABCB1) MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3Fd44xUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> MmTuNlUxPTh3Mk[=
SUDHL6  MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSx5qCK|ryP MlPSOFgwPzJiaB?= M1m5folvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M33mUlI1QTZzNkC0
SUDHL6  MkCxSpVv[3Srb36gRZN{[Xl? MofpNgKBkc7:TR?= M4ewZlczKGh? NVHvVG1zcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= NX3teWpGOjR7NkG2NFQ>
HCT-116 NUnqTlZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImxXVFIUTVyPUWgcm0> NH\QSWkzPDl{N{i1Oy=>
SKNBe2C MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLRb3ZkUUN3ME2zNk45yrF2LkCgcm0> MoLjNlQ6OjF7MkC=
IGNR91 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLQO2lKSzVyPUK0MlPDuTFwNzDuUS=> MkHFNlQ6OjF7MkC=
SKNAS M2nzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj5TWM2OD1zLkZCtVAvOiCwTR?= MXGyOFkzOTl{MB?=
LAN1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fEOGlEPTB;Mj6zxtExNjJibl2= NV7L[Y15OjR7MkG5NlA>
SHSY5Y NYGxN211T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;QbnVKSzVyPUiuNuKyOC54IH7N NYG0cIF6OjR7MkG5NlA>
A549-WT NWr1bmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXEUHRKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= M3;DeVI1QDV6OEK3
A549-R NHTQb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LB[WlEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= NXLldJBPOjR6NUi4Nlc>
MCF-7-WT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO1N|hKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= NEH1TVMzPDh3OEiyOy=>
MCF-7-R M4nFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrhdII3UUN3ME21MlU{QSEEsTCwMlE1PCBibl2= MWqyOFg2QDh{Nx?=
A549-R NV\VWoV{S3m2b4TvfIlkcXS7IFHzd4F6 NVmyVWNRUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= NX:2V3RCOjR6NUi4Nlc>
MCF-7-R Mm\KR5l1d3SxeHnjbZR6KEG|c3H5 M4DWWmlEPTB;NT61N|khyrFiMD6xOFQhdk1? MmLJNlQ5PTh6Mke=
SW620 NIm0NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTdwOECgxtEhOC5yODDuUS=> NHfaN5QzPDd{NkezPS=>
SW620/AD300 NV[0b2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTFOXlKSzVyPUmwPU43OCEEsTC4MlkyKG6P M3TDe|I1PzJ4N{O5
HEK293/pcDNA3.1 NWK0cWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnnXollUUN3ME2xMlQ2KMLzIECuNlAhdk1? MlLZNlQ4OjZ5M{m=
HEK293/ABCC1 NYq0[5ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSzUY8zUUN3ME2xPU4zQSEEsTCyMlA5KG6P NFOxOXAzPDd{NkezPS=>
TCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\aXFIzPCCq M{fDV2lEPTB;N{Cgcm0> MX[yOFcyPjl2NB?=
TCC NWHtfXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DmRlQ5KGh? NHO0cYJKSzVyPUWwJI5O NWnYc3RxOjR5MU[5OFQ>
HepG2/ADM MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYTGlEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP NYKwWXpVOjR5MES1OVY>
HepG2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfSfGdLUUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= M1[xSlI1PzB2NUW2
MCF-7/ADR NV7XcGFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS3dVl1UUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2= M3mxclI1PzB2NUW2
MCF-7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rI[WlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP NIXlWWkzPDdyNEW1Oi=>
A-172  MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf3NE4yyqEQvF2= M1\VNVI1Nzd{IHi= NH7pVY9qdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MVeyOFU{ODJ|NR?=
U-251MG NHXINGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMlHDqM7:TR?= MmPLNlQwPzJiaB?= NFjY[5lqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NEXzelAzPDV|MEKzOS=>
DLD-1 M3vCNmZ2dmO2aX;uJGF{e2G7 NYfTdJlTOTByIH7N NUKzOohHPDhiaB?= M1PXRZBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? M1TSe|I1PDB|NEWz
CCD18Co NXvnXWdETnWwY4Tpc44hSXO|YYm= M2DBU|ExOCCwTR?= NEPhZ3g1QCCq M4ftUZBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? MYCyOFQxOzR3Mx?=
DLD-1 NXPpc|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPcpgxNTFyMECgcm0> MXu0PEBp M{XDSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MoHRNlQ1ODN2NUO=
CCD18Co NXTB[4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMVExODBibl2= MV:0PEBp NH;xSZVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MXWyOFQxOzR3Mx?=
HepG2 NG[0OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j5eVI1KGh? MUXJR|UxRTV{LkZihKnPxE1? NH\ZcmUzPDN2MU[4PC=>
HEK293/pcDNA3.1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13KVWlEPTB;MD6wNFTDuTBwMECwN{DPxE1? NGjiOGszPDJ6NEe4Ny=>
HEK293/MRP1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEW1xtExNjBzMkCg{txO MYmyOFI5PDd6Mx?=
Ramos MWLBdI9xfG:|aYOgRZN{[Xl? NHjwcJAz6oDLzszN MlrYOFghcA>? MULpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> MoPZNlQzPTZ2OUG=
NCI-H1299/pcDNA3 NX71cXllS2WubDDWbYFjcWyrdImgRZN{[Xl? M3L3eVAuOjBibl2= MoLYPVYhcA>? NEPIOIlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NV7OOZpwOjRzN{ewNVI>
H1299/ICAM-3 NXPmV481S2WubDDWbYFjcWyrdImgRZN{[Xl? MojtNE0zOCCwTR?= NWfjO2I3QTZiaB?= MV7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MomyNlQyPzdyMUK=
NCI-H1299/pcDNA3 MULGeY5kfGmxbjDBd5NigQ>? NV\YNnFwOS93L{GwM|IxyqCwTR?= M{nDRlk3KGh? M17tRolv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> M1vhUVI1OTd5MEGy
H1299/ICAM-3 M{POU2Z2dmO2aX;uJGF{e2G7 MWixM|UwOTBxMkFCpI5O NHXKbYQ6PiCq NGe4TlFqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR M4XXR|I1OTd5MEGy
W1 NY\pU4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mzWmlEPTB;MD6wNFMzKM7:TR?= MUSyOFE1ODF5Nh?=
W1VR M3vHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXXVXNIUUN3ME2wMlA2PiEQvF2= Mnn0NlQyPDBzN{[=
K562 M1\MOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7tWWVqUUN3ME2wMlA{OiEEsTCwMlAxOSBizszN NEn2cVEzPDF|NUmzOy=>
K562/ADR NGHUNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jCcmlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP M2f0S|I1OTN3OUO3
K562 NWe2ZWVFSXCxcITvd4l{KEG|c3H5 NV;ad3BOOC5|IN88US=> NVXJVGllOjRiaB?= MVLpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MknBNlQyOzV7M{e=
K562/ADR NX\PW2hJSXCxcITvd4l{KEG|c3H5 Mn3zN{DPxE1? NVO3boFLOjRiaB?= MX\pcoR2[2W|IHHwc5B1d3Orcx?= MoLHNlQyOzV7M{e=
A549 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD1yLkGwJOKyKDBwMEOg{txO NGfoOoczOzl5MUC3OS=>
K562 MlXPR4VtdCCYaXHibYxqfHliQYPzZZk> M{DFcVMvPzYkgKO2NOKhdk1? NWGwTVBqPzMEoHlCpC=> NITpWW9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MlXDNlM5Pzd{MkO=
lucena MnTkR4VtdCCYaXHibYxqfHliQYPzZZk> NWjMcJNrOy55NfMAl|YxyqCwTR?= M{P2T|czyqCqwrC= MoL3co8h\W[oZXP0 NYXOXpUzOjN6N{eyNlM>
FEPS NYK0eZg3S2WubDDWbYFjcWyrdImgRZN{[Xl? NHnkTIw{Njd34pETOlDDqG6P MnjUO|LDqGkEoB?= NWPDbFFVdm9iZX\m[YN1 NF\5RZczOzh5N{KyNy=>
A2780 NYrVPXZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULv[mZZUUN3ME2zMlUhdU1? M4r0dFI{QDJ7MkCz
ACHN Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLBR45KSzVyPECuNUBuVQ>? MUCyN|gzQTJyMx?=
U-937 M4jadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jkUGlEPTB:M{Sgcm0> MlfRNlM5Ojl{MEO=
Jurkat MWDBdI9xfG:|aYOgRZN{[Xl? MVG1xsDPxGdxbX|CpC=> MoDzNlQhcA>? NWftN3JCcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NIjSdYozOzhzMESwPS=>
Jurkat MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz4OeKh|rypL33sxsA> MlnONlQhcA>? NEfZ[lJienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= M{jVXFI{QDFyNEC5
Hep-2 M4\nXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEVCtVAvODFizszN MYCyN|c5ODR{NB?=
Hep-2/v NVuxZmZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:2NWlEPTB;MT64xtExNjJyIN88US=> NUGzb2pVOjN5OEC0NlQ>
SGC-7901 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DveVAuOTBizsznM41t NWG0d5FZOjRxNEivO|IhcA>? NFrXenlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWqyN|c1OzV5Mh?=
SGC-7901/VCR NWfFRYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP6XJMxNTFyIN88[{9udA>? MmLYNlQwPDhxN{KgbC=> MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MnjGNlM4PDN3N{K=
SGC-7901 MlnERZBweHSxc3nzJGF{e2G7 NWPufY54cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M3jrflI{PzR|NUey
SGC-7901/VCR MUfBdI9xfG:|aYOgRZN{[Xl? M2e0TYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NHnE[nUzOzd2M{W3Ni=>
KB-3-1 M1Oxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[x[FVKSzVyPUGuOlYhyrFiMD6xOlIh|ryP MV6yN|Y4OzR2NR?=
KB-C2 M2Lpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13zS2lEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= MoLBNlM3PzN2NEW=
KB-3-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? MX2yN|Y4OzR2NR?=
KB-V1 NGDUTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\MOGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP NIPyXVEzOzZ5M{S0OS=>
HEK293/pcDNA3.1 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof1TWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? M2jlWlI{Pjd|NES1
HEK293/ABCB1 NFy5N25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= NWDmR|BFOjN4N{O0OFU>
A549/EGFP  M4PwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\tNE4xOS1zMECwJO69VQ>? NWfGTVJIUUN3ME24Ok44KMLzIEK5MlEh|ryP Ml3nNlM3OzR{OEK=
A549/Slug M1;JTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr3PVhwOC5yMT2xNFAxKM7:TR?= M2XZWWlEPTB;OT63JOKyKDNwMTFOwG0> NH3tcIQzOzZ|NEK4Ni=>
JFCR39  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP4NUDDvU1? MX:yOEBp NXHB[HZYTE2VTx?= MnLJcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? NXrtXmVuOjN3OUiyO|Y>
A549 Ml6ySpVv[3Srb36gRZN{[Xl? NIj1Z4cyODBibl2= MWexOkBp NGfROmVFVVOR Mo\NcIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? M1vYPVI{PTl6Mke2
SGC7901 NUTUfmk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrNSG5KSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t NFXZRY0zOzV4NES4Ni=>
SGC7901/LV-NC NE\ZbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXRTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> M4jrTFI{PTZ2NEiy
SGC7901/LV-SGO1 NHWzdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfLZZNKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t MYOyN|U3PDR6Mh?=
SGC7901/VCR NEfSN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmwXXpKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? M2nJeVI{PTZ2NEiy
SGC7901/VCR-NC NWLv[VAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyRYNKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? NFHVU4czOzV4NES4Ni=>
SGC7901/VCR-si-SGO1 M1qwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr4bmZLUUN3ME22MlE56oDLwsJihKkyNjB|IN88[{9udA>? M1Lj[lI{PTZ2NEiy
SGC7901/ADR MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;V[JRKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t NFTrSJczOzV4NES4Ni=>
SGC7901/ADR-NC M4\XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzINldtUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? MkX1NlM2PjR2OEK=
SGC7901/ADR-si-SGO1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInENHpKSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t M2i2R|I{PTZ2NEiy
SH-SY5Y  NGjuNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf3cI02OC5yMEGtNVAh|ryP MkK1NlQhcA>? M3rXbGlEPTB;MD6xNVPDuTBwMEGyJO69VQ>? MVKyN|EzQTB4NR?=
SH-SY5Y  MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhXlFEOC5yMEGtNVAh|ryP M3SyXlQ5KGh? M1yz[mlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? NIrrWpIzOzF{OUC2OS=>
SH-SY5Y  NVLLeZFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnMNE4xODFvMUCg{txO Mn7JO|IhcA>? M1zwfmlEPTB;MD6wOVHDuTBwMEC4JO69VQ>? NUi4ZmkyOjNzMkmwOlU>
SH-SY5Y NFLHSIlCeG:ydH;zbZMhSXO|YYm= MY[wMlEh|ryP NXnCcXV{OC1{NDDo MVrpcoR2[2W|IHHwc5B1d3OrczDv[kBUUC2VWUXZJINmdGy|IH\vcIxwf2mwZzDj[YxtKGO7Y3zlJIFzemW|dDDheEB1cGViR{KvUUBxcGG|ZR?= MXyyN|EzQTB4NR?=
SH-SY5Y M1;4fmFxd3C2b4Ppd{BCe3OjeR?= M2LNVVAvOSEQvF2= M3PwPVAuOjRiaB?= MVzpcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? MX6yN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03519984 Recruiting Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic/Myeloproliferative Neoplasm|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|T Acute Lymphoblastic Leukemia University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics Inc|Whittier Foundation May 9 2018 Phase 1
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT01397825 Completed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt''s Lymphoma Millennium Pharmaceuticals Inc.|Takeda August 9 2011 Phase 1|Phase 2
NCT02564484 Recruiting Leukemia|Lymphoma St. Jude Children''s Research Hospital|University of Chicago|National Cancer Institute (NCI) February 8 2016 --
NCT03399747 Enrolling by invitation Diffuse Large B-cell Lymphoma Asan Medical Center December 7 2016 Phase 2
NCT01527149 Active not recruiting Stage I Mantle Cell Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma Roswell Park Cancer Institute|National Cancer Institute (NCI)|National Comprehensive Cancer Network December 6 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID